Biology and Treatment of Myeloid Leukaemias / / edited by Geoffrey Brown and Ewa Marcinkowska.
There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the can...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel, Switzerland : : MDPI,, 2018. |
Year of Publication: | 2018 |
Language: | English |
Physical Description: | 1 online resource (vi, 190 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993561962404498 |
---|---|
ctrlnum |
(CKB)5400000000000211 (NjHacI)995400000000000211 (EXLCZ)995400000000000211 |
collection |
bib_alma |
record_format |
marc |
spelling |
Biology and Treatment of Myeloid Leukaemias / edited by Geoffrey Brown and Ewa Marcinkowska. Basel, Switzerland : MDPI, 2018. 1 online resource (vi, 190 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy. Carcinogens. Marcinkowska, Ewa, editor. Brown, Geoffrey, editor. |
language |
English |
format |
eBook |
author2 |
Marcinkowska, Ewa, Brown, Geoffrey, |
author_facet |
Marcinkowska, Ewa, Brown, Geoffrey, |
author2_variant |
e m em g b gb |
author2_role |
TeilnehmendeR TeilnehmendeR |
title |
Biology and Treatment of Myeloid Leukaemias / |
spellingShingle |
Biology and Treatment of Myeloid Leukaemias / |
title_full |
Biology and Treatment of Myeloid Leukaemias / edited by Geoffrey Brown and Ewa Marcinkowska. |
title_fullStr |
Biology and Treatment of Myeloid Leukaemias / edited by Geoffrey Brown and Ewa Marcinkowska. |
title_full_unstemmed |
Biology and Treatment of Myeloid Leukaemias / edited by Geoffrey Brown and Ewa Marcinkowska. |
title_auth |
Biology and Treatment of Myeloid Leukaemias / |
title_new |
Biology and Treatment of Myeloid Leukaemias / |
title_sort |
biology and treatment of myeloid leukaemias / |
publisher |
MDPI, |
publishDate |
2018 |
physical |
1 online resource (vi, 190 pages) |
isbn |
3-03842-796-9 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC268 |
callnumber-sort |
RC 3268.6 B565 42018 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.994071 |
dewey-sort |
3616.994071 |
dewey-raw |
616.994071 |
dewey-search |
616.994071 |
work_keys_str_mv |
AT marcinkowskaewa biologyandtreatmentofmyeloidleukaemias AT browngeoffrey biologyandtreatmentofmyeloidleukaemias |
status_str |
n |
ids_txt_mv |
(CKB)5400000000000211 (NjHacI)995400000000000211 (EXLCZ)995400000000000211 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Biology and Treatment of Myeloid Leukaemias / |
author2_original_writing_str_mv |
noLinkedField noLinkedField |
_version_ |
1764990387867353089 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02225nam a2200289 4500</leader><controlfield tag="001">993561962404498</controlfield><controlfield tag="005">20230223220639.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230223s2018 sz o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03842-796-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000000211</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000000211</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000000211</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC268.6 </subfield><subfield code="b">.B565 2018</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.994071</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Biology and Treatment of Myeloid Leukaemias /</subfield><subfield code="c">edited by Geoffrey Brown and Ewa Marcinkowska.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel, Switzerland :</subfield><subfield code="b">MDPI,</subfield><subfield code="c">2018.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (vi, 190 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Carcinogens.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marcinkowska, Ewa,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brown, Geoffrey,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 00:32:40 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-10-31 22:37:04 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338373650004498&Force_direct=true</subfield><subfield code="Z">5338373650004498</subfield><subfield code="8">5338373650004498</subfield></datafield></record></collection> |